Expression Profiling Identified TRPM7 and HER2 as Potential Targets for the Combined Treatment of Cancer Cells
TRPM7 is a divalent cation-permeable channel that is highly active in cancer cells. The pharmacological inhibitors of TRPM7 have been shown to suppress the proliferation of tumor cells, highlighting TRPM7 as a new anticancer drug target. However, the potential benefit of combining TRPM7 inhibitors w...
Saved in:
| Main Authors: | Miyuki Egawa, Eva Schmücker, Christian Grimm, Thomas Gudermann, Vladimir Chubanov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/13/21/1801 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors
by: Kristian Egebjerg, et al.
Published: (2025-08-01) -
HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top
by: Pamela Trillo Aliaga, et al.
Published: (2025-06-01) -
Successful Treatment of HER2 V659E Mutation‐Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report
by: Mariko Nishihara, et al.
Published: (2025-06-01) -
Trastuzumab monotherapy as maintenance treatment for metastatic HER2+ vulvar Paget disease: systematic review and case report
by: Dalila Incognito, et al.
Published: (2025-06-01) -
ERBB3-related gene PBX1 is associated with prognosis in patients with HER2-positive breast cancer
by: Shufen Mo, et al.
Published: (2025-01-01)